Reccan Joins EU-Led SHIELD Project to Revolutionize Early Pancreatic Cancer Detection

Reccan AB announces its pivotal role in the launch of SHIELD, a €14 million, Horizon Europe-funded project dedicated to transforming the early detection of pancreatic cancer across Europe. The initiative brings together 26 partners from 13 countries, all focused on improving survival rates through proactive diagnostics in high-risk individuals. 

Driving Innovation in Early Detection
At the heart of SHIELD is Reccan-IA, a cutting-edge blood-based multiplex immunoassay developed by Reccan. This non-invasive test has demonstrated 92% sensitivity and 96.8% specificity in initial studies—promising a leap forward in the early diagnosis of pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancer types. 

“Being funded is a proof of the importance to find pancreatic cancer at an early stage when it is still treatable and strengthens Reccan’s mission to develop a blood-based, easily accessible detection test,” says Anna Brodén, CEO of Reccan. 

Reccan-IA will now enter clinical validation in a pan-European cohort of over 1,000 individuals with a strong genetic or familial predisposition to pancreatic cancer. 

“By shifting from reactive to proactive diagnostics, Reccan is committed to delivering impactful innovations that save lives and reduce healthcare burdens,” said Professor Roland Andersson, Reccan founder and clinical lead of SHIELD. 

SHIELD: A Paradigm Shift in Cancer Screening
The SHIELD program will implement structured screening pilots in seven EU countries, offering annual blood tests for genetically high-risk individuals. It aims to reduce late-stage diagnoses and ultimately increase the five-year survival rate from less than 10% to 30% by 2035. 

Reccan’s work in SHIELD reflects its unwavering mission to make early, accessible detection a standard for pancreatic cancer prevention. 

Reccan is participating in SmiLe's incubator program.